TOI
insider transactionsOncology Institute, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-11.5K
12.0K buy · 23.5K sell
Net value · 30d
-$69.1K
$57.0K in · $126.1K out
Sentiment · 30d
Net selling
31% buying · 69% selling
Open-market trades · 30d
2
12.0K buy · 23.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Medical Officer · 10b5-1
$126.1K
23.5K sh · $5.38
Own -8%
-
Buy·P
10% Owner
$57.0K
12.0K sh · $4.75
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Yale Podnos 10b5-1 | Sell S | 23.5K | $126.1K |
| Jun 4, 2026 | Jorey Chernett | Buy P | 12.0K | $57.0K |
About TOI insider trading
This page tracks insider transactions for Oncology Institute, Inc. (TOI) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.